Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
108.09
(
0.57%
)
Bitcoin
76,997.31
(
-0.53%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

entdoc

Send PM Follow Ignore
Followers 38
Posts 1440
Boards Moderated 0
Alias Born 03/07/2004

entdoc

Re: asmarterwookie post# 43980

Wednesday, 10/28/2009 5:04:06 PM

Wednesday, October 28, 2009 5:04:06 PM

Post# of 347009
Serious allergic reactions to administered chimeric MABs now on the market [ie Erbitux] are acknowledged to be about 5%. It appears that even patients with pre-existing "mouse anti-bodies" [most of the world's population] may have an average 44 day window of treatment before incidence of reactions spikes. This is my own conclusion from skimming the data.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote